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doi:10.1016/j.jmii.2011.09.019Background and Purpose: This study was conducted to investigate the molecular epidemiology
and antimicrobial susceptibility of multidrug-resistant (MDR) Acinetobacter baumannii to
three types of antibiotics.
Methods: One hundred and thirty-four specimens of MDR A baumannii were collected from
three branches (Taipei, Dalin, and Hualien branches) of Buddhist Tzu Chi Hospital, which
are located in northern, southern, and eastern Taiwan, during 2007. Genotyping was per-
formed by pulsed-field gel electrophoresis. Antibiotic susceptibilities to colistin, rifampicin,
and tigecycline were determined. The synergistic effects of rifampin and colistin were also
evaluated.
Results: Antibiotic susceptibility testing showed that 10.4%, 47.8% and 45.5% of the MDR A bau-
mannii isolates are resistant to colistin, rifampicin, and tigecycline, respectively. A majority of
the rifampicin-resistant isolates (62.7%) were found in the Haulien branch, whereas 62.2% of
tigecycline-resistant isolates were found in the Taipei branch. The combination of colistin
and rifampicin had a synergistic effect on all of the isolates. Genotyping by pulsed-field gelof Medical Laboratory Science and Biotechnology, Yuanpei University, Number 306, Yuanpei Street,
m (M.-L. Liou).
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38 K.-C. Chang et al.electrophoresis identified 17, 23, and 11 pulsotypes in the Taipei, Dalin, and Haulien branches,
respectively. Furthermore, 74.5% of isolates in the Haulien branch were identified as one of
three pulsotypes. Among 37 rifampicin-resistant and 22 tigecycline-resistant MDR A baumannii
isolates found in the Haulien branch, 51.3% (19/37) and 50% (11/22) of the isolates belonged to
the same clone, respectively.
Conclusion: This study confirms the high prevalence of resistance to rifampicin and tigecycline
in MDR A baumannii in the three hospitals that were studied, and the high proportion of iden-
tical strains that exist in eastern Taiwan.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Acinetobacter baumannii has emerged as an important
multidrug-resistant (MDR) pathogen that is responsible for
hospital-acquired infections.1,2 Common infections include
ventilator-associated pneumonia, bacteremia, and infec-
tions in and around burn wounds and the urinary tract.3 The
epidemic potential of A baumannii is primarily related to
this organism’s ability to develop resistance to a variety
of antimicrobial agents, including broad-spectrum
cephalosporins, carbapenems, fluoroquinolones, and
aminoglycosides.4
Carbapenem, imipenem, and meropenem, remain the
drugs of choice for the treatment of A baumannii.5
However, the efficacy of these drugs can be compromised
by the spread of carbapenemases,6,7 a situation which
urgently requires other antibiotic options. Several studies
have shown that three antibioticsdtigecycline, rifampicin
and colistindare effective against carbapenem-resistant
strains of A baumannii.8e10 However, the reduced suscep-
tibility to these three drugs in A baumannii has recently
been reported in several countries.11,12 Nevertheless,
several studies have shown that tigecycline- or rifampicin-
based regimens are more effective for treating severe
infections caused by MDR A baumannii.13,14 To date, no
studies are available on the efficacy of rifampicin or
combination rifampicin/colistin against A baumannii
isolates in Taiwan, although rifampicin has been used for
the long-term treatment of infections caused by Mycobac-
terium tuberculosis. Furthermore, the spread of MDR
A baumannii with resistance to tigecycline, rifampicin, and
colistin in hospitals has never been reported in Taiwan.
The goal of this study is to compare the susceptibility of
MDR A baumannii to colistin, rifampicin, tigecycline, and
combination colistin/rifampicin at three hospitals in
northern, southern, and eastern Taiwan. The molecular
epidemiologies of each of these isolates were also further
investigated in each hospital.
Methods
Definition
A baumannii is defined as multidrug-resistant when the
organism is resistant to piperacillin, piperacillin-tazobactam,
ampicillin/sulbactam, imipenem, ceftazidime, gentamicin,
amikacin, tetracycline, chloramphenicol, ciprofloxacin, and
cotrimoxazole.15Hospital settings and bacterial isolates
This study analyzed MDR Acinetobacter spp. Samples were
nonrepetitively collected from three branches of Buddhist
Tzu Chi General Hospital in Taiwan. Hualien Tzu Chi Medical
Center (Haulien branch) is a 966-bed university hospital
located in eastern Taiwan. The Taipei branch is an 890-bed
regional hospital in northern Taiwan. The Dalin branch is an
896-bed regional hospital in southern Taiwan. The infection
control policies regarding MDR Acinetobacter spp.,
including contact precautions, were the same at each
hospital. All clinical MDR Acinetobacter spp. isolates
collected during 2007 were stored at 80 C in trypticase
soy broth (Difco Laboratories, Detroit, MI, USA) that was
supplemented with 20% glycerol before testing. All isolates
were transported to the clinical microbiology laboratory at
Tzu Chi University for further study.Identification and antimicrobial susceptibilities
The clinical strains of Acinetobacter spp. collected at the
Haulien branch were isolated and identified using the
Phoenix system (Becton Dickinson Diagnostic Systems,
Sparks, MD, USA); isolates from the Taipei and Dalin
branches were identified using the Vitek system (Bio-
merieux Vitek, Inc., Hazelwood, MO, USA). Characteriza-
tion of these isolates as A baumannii or non-A baumannii
spp. was performed using one-tube multiplex PCR, based on
the method described by Chen et al.16 Susceptibilities to
tigecycline, colistin, and rifampicin were determined using
the broth-dilution method, in accordance with the guide-
lines of the Clinical and Laboratory Standards Institute
(CLSI).17 In vitro interaction of colistin with rifampicin was
assessed by the checkerboard method, as previously
described.8 Escherichia coli ATCC 25922 and Pseudomonas
aeruginosa ATCC 27853 were used as the reference strains
for susceptibility testing. The breakpoints for Enter-
obacteriaceae, which are approved for use by the U.S.
Food and Drug Administration, were applied in order to
define tigecycline susceptibility (susceptibility, 2 mg/L;
resistance, 8 mg/L).18 The breakpoints for colistin
were those recommended by the CLSI guidelines (suscep-
tibility, 2 mg/L; resistance, 4 mg/L).19 Breakpoints
for rifampicin were those recommended by CLSI for staph-
ylococci (susceptibility, 1 mg/L; resistance, 4 mg/L).20
The effects of synergism, indifference, and antagonism
due to combination colistin/rifampicin were previously
defined.8
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Pulsed-field gel electrophoresis (PFGE) was performed
using genomic DNA from all of the multidrug-resistant
Acinetobacter isolates, as previously described.21 Chromo-
somal DNA plugs were incubated with ApaI endonuclease.
Restriction fragments were separated by PFGE in 1% Sea-
kem Gold (SKG) agarose and run in a 0.5 Tris-borate-EDTA
buffer on a CHEF-DRIII system (Bio-Rad Laboratories,
Hercules, CA). The initial switch time was 5 seconds, the
final switch time was 20 seconds, and the run time was
21.5 hours at 6 V/cm. The gel was stained with ethidium
bromide, washed in distilled water, and photographed
under ultraviolet (UV) light. The PFGE banding patterns
were interpreted according to previously described
criteria.22 Saved.tiff files of the photographed gels were
further analyzed by Molecular Analyst 1.6 software (Bio-
Rad). The percentage similarity was identified using the
dendrogram-derived unweighted pair-group method using
arithmetic means based on Jaccard coefficients. Both band
position tolerance and optimization were calibrated at
1.0%. Isolates with PFGE band similarity >80% were classi-
fied as the same type.
Results
Antimicrobial susceptibility testing
A total of 134 MDR Acinetobacter spp. samples, including
37, 38, and 59 isolates from the Taipei, Dalin, and Hualien
Branches of Buddhist Tzu Chi General Hospital, respec-
tively, were collected in 2007. All of the isolates were
identified as A baumannii according to the presence of an
internal 208-bp fragment from the Intergenic spacer (ITS)
region that had been previously described by Chen et al.16
The antimicrobial susceptibility test showed that 10.4%,
47.8% and 45.5% of the MDR A baumannii isolates were
resistant to colistin, rifampicin, and tigecycline, respec-
tively (Table 1). Resistance to the three antimicrobials
varied at each of the three hospitals. All of the MDR ATable 1 Antibiotic susceptibilities of MDR A baumannii strains is
to colistin, rifampicin, and tigecycline
Hospital Haulien brancha
(n Z 59)
T
Antimicrobials
(Resistance breakpoints) R R
Colistind (4) 8 (13.6) 6
Rifampicind (4) 37 (62.7) 1
Tigecycline (8) 22 (37.3) 2
Colistin þ rifampicin 6 (10.2) 0
Colistin þ tigecycline 4 (6.8) 2
Rifampicin þ tigecycline 9 (15.6) 7
All 4 (6.8) 0
a Eastern Taiwan.
b Northern Taiwan.
c Southern Taiwan.
d The synergistic effects on all of the isolates were tested.baumannii isolates taken from the Dalin branch were
susceptible to colistin. A majority of the rifampicin-
resistant isolates (62.7%) were found in the Hualien
branch, whereas 62.2% of isolates found at the Taipei
branch were resistant to tigecycline. Furthermore, colistin
displayed a synergistic effect with rifampicin in all of the
isolates tested.PFGE typing
Genotyping revealed that a total of 17, 23, and 11 different
pulsotypes were identified in the Taipei, Dalin and Haulien
branches, respectively (Table 2). The distribution of the
pulsotypes among the three branches differed substan-
tially. Strains found in Dalin branch were more heteroge-
neous, with 23 pulsotypes identified among 38 isolates;
more homogeneous strains were found in the Haulien
branch, with 11 pulsotypes identified among 59 isolates.
The percentages of MDR Acinetobacter isolates identified as
one pulsotype that contained six or more isolates was 19.8%
(7/37) and 74.5% (44/59) in the Taipei and Hualien
branches, respectively (Table 2).
The pulsotypes of the rifampicin-resistant MDR A bau-
mannii strains identified in the three hospitals were further
investigated, and the results are shown in Table 3. Of the 37
rifampicin-resistant MDR A baumannii isolates obtained
from the Haulien branch, 19 (51.3%) belonged to the same
clone, whereas more heterogeneous rifampicin-resistant
isolates were found in the other branches.
The pulsotypes of the tigecycline-resistant MDR A bau-
mannii strains in the three hospitals were also analyzed
(Table 3). Of the 22 tigecycline-resistant MDR A baumannii
isolates obtained at the Haulien branch, 11 (50%) belonged
to the same clone. In contrast, those isolates with more
heterogeneous pulsotypes were found in the other two
branches.
The pulsotypes of the colistin-resistant MDR A baumannii
strains found in the Haulien and Taipei branches were
examined. All these strains were unrelated to the strains
found in the other two hospitals.olated from three branches of Buddhist Tzu General Hospital
aipei branchb
(n Z 37)
Dalin branchc
(n Z 38)
Total
(n Z 134)
No. of isolates (%)
R R
(16.2) 0 (0) 14 (10.4)
0 (27.0) 17 (44.7) 64 (47.8)
3 (62.2) 16 (42.1) 61 (45.5)
(0) 0 (0) 6 (4.5)
(5.4) 0 (0) 6 (4.5)
(18.9) 12 (31.6) 28 (20.9)
(0) 0 (0) 4 (3)
Table 2 Pulsotypes of MDR A baumannii obtained from
three branches of Buddhist Tzu Chi Hospital
Branch No. of
isolates
No. of isolates in
one pulsotype
No. of
pulsotypes
Taipei 37 17
1 10
2 1
3 2
4 3
7 1
Dalin 38 23
1 13
2 7
3 1
4 2
Hualian 59 11
1 5
2 1
3 1
5 1
9 1
13 1
22 1
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The increasing large number of reports detailing the
emergence of MDR A baumannii indicates a significant
public health concern.2 Typically, tigecycline and colistin
are used to treat MDR A baumannii infections as a result of
limited antibiotic choices. One study conducted on
19 hospitals in Taiwan during 2006 showed that 6.9% of
A baumannii strains are resistant to tigecycline.23 Another
report conducted on three medical centers in TaiwanTable 3 Distribution of MDR A baumannii with rifampin and/o
Hospital
Branch Rifampicin resistance
No. of
isolates
No. of isolates in
one pulsotype
No. of
pulsotyp
Taipei 10 5
1 3
3 1
4 1
Dalin 17 13
1 9
2 4
Hualien 37 11
1 6
2 2
3 1
5 1
19 1between 2001 and 2005 showed that the resistance rates of
imipenem-non-susceptible A baumannii to tigecycline and
colistin were 18% and 1%, respectively.24 The present study
reveals that 45.5% and 10.4% of MDR A baumannii isolates
are resistant to tigecycline and colistin, which is much
higher than previously reported.23,24 The high prevalence of
tigecycline and colistin resistance in this study might be
due to the selection criteria for MDR strains that were used
compared with the criteria used by Liu et al.23 However,
the gradual increase of tigecycline and colistin-resistant
MDR A baumannii in Taiwan is alarming. Strict regulations
regarding the use of tigecyclin began in each of the three
branches in 2007. However, the rates of resistance to
tigecycline in MDR A baumannii among the three hospitals
in our study are clearly different. In Taiwan, many medical
centers are located in the greater Taipei area. Tigecycline
began to be used much earlier in the hospitals located in
and around Taipei than in hospitals located farther away
from Taipei. This may be one of the reasons for the higher
rate of resistance to tigecycline found among MDR A bau-
mannii isolates obtained from the Taipei branch of Buddhist
Tzu Chi Hospital.
Rifampicin has been used solely for the treatment of
M. tuberculosis infections for more than three decades in
Taiwan. However, because MDR A baumannii infections are
associated with an increase in attributed mortality and due
to the limited treatment options available for this disease,
rifampicin-based regimens have been proposed as an
alternative treatment.9 One report on the development of
rifampicin resistance in MDR A baumannii showed that
rifampicin-resistant mutants are found after 48e72 hours
of in vitro and in vivo exposure to rifampicin.25 In spite of
the lack studies on rifampicin exposure, up to 47.7% of
MDR A baumannii isolates identified in this study are
resistant to rifampicin. In addition, this study is the first
report the high prevalence of rifampicin-resistant MDR
A baumannii in Taiwan. The high resistance rate of MDRr tigecycline resistance in each branch of Buddhist Tzu Chi
Tigecycline resistance
es
No. of
isolates
No. of isolates in
one pulsotype
No. of
pulsotypes
23 11
1 5
2 2
3 3
5 1
16 11
1 7
2 3
3 1
22 8
2 4
1 5
3 2
11 1
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Giamarellos-Bourboulis et al.26 The reason for choosing
combination colistin/rifampicin instead of tigecycline in
combination with colistin or rifampicin is based on the find-
ings of a previous report that showed a lower percentages of
synergistic combinations with tigecycline were observed
when in combination with colistin (11%) or rifampicin (11%).8
Meanwhile, Bassetti et al27 showed that combination
colistin/rifampicin is effective against MDR A baumannii,
which is consistent with the findings presented here.
The intrahospital dissemination of MDR A baumannii has
been reported by several studies conducted in southern,
central, and northern Taiwan.28,29 Nevertheless, the
localized spread of MDR A baumannii strains in eastern
Taiwan remains unclear. This study shows that 74.5% of the
isolates found in the Haulien branch belong to three pul-
sotypes, even if no evidence of outbreak was noted. This
suggests that an outbreak or cross-transmission between
patients in this hospital could have occurred. Thus, it is
urgent to monitor and control the spread of MDR A bau-
mannii in the hospitals of eastern Taiwan through timely
antimicrobial resistance surveillance and strict infection-
control strategies.
The spread of MDR A baumannii with resistance to
tigecycline, colistin, and rifampicin is an important issue
that hospitals must control. Such epidemiological surveil-
lance is still lacking in Taiwan, despite the alarming
emergence of drug-resistant strains of A baumannii,
particularly among those isolates that are not susceptible
to tigecycline or colistin.28 This study shows that the spread
of rifampicin- and tigecycline-resistant MDR A baumannii
isolates varies between the three hospitals. More hetero-
geneous MDR A baumannii isolates were obtained from the
Taipei and Dalin branches. These two hospitals receive
more patients that are transferred from nearby, smaller
hospitals. Such transfers could result in the interhospital
transmission of strains. In contrast, the intrahospital
dissemination of MDR A baumannii might account for the
clonal spread of rifampicin- and tigecycline-resistant
isolates with different pulsotypes in the Hualien branch.
This phenomenon emphasizes the importance of imple-
menting effective infection-control strategies that could
reduce clonal spread within hospitals.
In conclusion, the results of this study provide the first
direct evidence of the clonal spread of tigecycline- and
rifampicin-resistant MDR A baumannii within hospitals in
eastern Taiwan. Alarmingly high rates of resistance to
tigecycline and rifampicin in MDR A baumannii isolates
were found in three hospitals located in different areas of
Taiwan. The spread of tigecyline- and rifampicin-resistant
MDR A baumannii strains via intra- and interhospital
transmission warrants further investigations.Acknowledgments
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